Treventis' Grant

Treventis raised a round of funding on September 19, 2013. Investors include Wellcome Trust.

Treventis has leveraged a drug design platform to synthesize a class of organic drug-like molecules with the capability of binding to both beta-amyloid and tau, preventing aggregation of both proteins…

Articles about Treventis' Grant: